Foreign medical residents fill critical positions at US hospitals, but are running into visa issues
It's unclear exactly how many foreign medical residents were unable to start their assignments, but six medical residents interviewed by The Associated Press say they've undergone years of training and work only to be stopped at the finish line by what is usually a procedural step.
'I don't want to give up,' said a permanent Canadian resident who matched to the University of Pittsburgh Medical Center Harrisburg but had her visa denied because she is a citizen of Afghanistan. She requested to remain anonymous for fear of reprisal. 'But the situation also seems so helpless.'
Initially, the medical community was worried that hundreds of positions — many in hospitals in low-income or rural areas of the U.S. — could be affected. The pause on interviews for J-1 visas for approved work or study-related programs was lifted in mid-June.
The national nonprofit that facilitates the residency match process said the visa situation is resolving, but it will take weeks to know with confidence how many medical residents have had the start of their careers derailed because they got their visa too late or were blocked by President Donald Trump's travel ban on 12 countries, according to people who coordinate the residents' training.
Four foreign medical residents told the AP that U.S. embassies have been slow to open up interview slots — and some have not opened any.
'You lose out on the time you could have used to treat patients,' said one resident from Pakistan, who matched to an internal medicine program in Massachusetts and requested to remain anonymous for fear of reprisal.
Thousands of foreign medical residents fill gaps in U.S. hospitals
The U.S. is projected to face a physician shortage in the next 11 years, per the Association of American Medical Colleges, and foreign medical residents fill critical gaps in the health care system. More than 6,600 foreign-born international medical residents matched into U.S. programs in 2025 — the highest on record — and another 300 filled positions that were vacant after the match process was complete.
Not all of those residents were affected by visa issues or the travel ban on foreign nationals from countries including Afghanistan, Haiti and Sudan.
International medical graduates often take jobs in places where U.S. medical trainees tend not to go, said Donna Lamb, president of the National Resident Matching Program.
'It's not just that they're coming in and they want to work in big, flashy centers on the coast,' Lamb said. 'They're truly providing health care for all of America.'
Foreign medical residents work in specialties that U.S. applicants aren't as eager to apply to. For example, international candidates make up almost 40% of residents in internal medicine, which specializes in the prevention and treatment of chronic conditions like diabetes and heart disease.
'The residents are the backbone of the entire hospital,' said Dr. Zaid Alrashid from Brookdale University Hospital and Medical Center in New York, which has medical residents from almost every continent. Most received their visas prior to the pause but a few were caught up in delays.
Two residents from India who spoke on condition of anonymity have not been able to get an appointment at any U.S. embassies there despite the J-1 visa pause being lifted.
Another resident from Egypt just secured a visa appointment for mid-August but is worried her program may not be willing to wait for her. She's already paid her security deposit for an apartment in Texas to live during her residency.
'I don't know when this situation will be resolved,' said the resident, who spoke on condition of anonymity, adding she hasn't been eating or sleeping well.
Hospitals waiting for residents to arriveIn California, leaders at two graduate medical education programs said they have a small number of residents caught up in J-1 visa delays. Both spoke on condition of anonymity due to concerns for the doctors who are still trying to get visas.
A residency leader at one large health care system said two doctors in its 150-resident program are delayed, adding they could start late or defer to next year. A 135-person program at a California public health system told the AP that one resident has yet to arrive, though he was finally scheduled for a visa interview.
'We are not going to breathe easy until he's here in our hospital,' the second leader said.
As of Wednesday, Lamb's matching program had received fewer than 20 requests to defer or cancel residency contracts.
Worried about losing their spots if they defer, many foreign medical residents may keep trying to get to the U.S. and start their residencies late, said Dr. Sabesan Karuppiah, a past member of the American Medical Association's International Medical Graduates Governing Council and former director of a large residency program.
Some hospitals may struggle at this point to replace the residents who don't make it, leaving fewer people to care for the same number of patients, said Kimberly Pierce Burke, executive director of the Alliance of Independent Academic Medical Centers.
Foreign medical trainees who've made it into the U.S. remain on edge about their situations, Karuppiah said.
'I can tell you the word on the street is: 'Do not leave the country,'' he said, adding that people are missing out on important events, seeing sick parents or even getting married. 'Everybody's scared to just leave, not knowing what's going to happen.'
—-
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas
Abbott Laboratories (NYSE:ABT) is one of the high profit margin stocks to buy now. On June 19, Beta Bionics Inc. (NASDAQ:BBNX) announced its plan to integrate its iLet Bionic Pancreas automated insulin delivery/AID system with Abbott's future dual glucose-ketone sensor in the US. The collaboration aims to enhance real-time decision-making support for individuals with diabetes. The iLet Bionic Pancreas received FDA clearance in May 2023 and is distinguished as the first and only AID system that autonomously makes 100% of insulin dosing decisions. This eliminates the need for carb counting or manual insulin correction calculations for users, though they still need to be 'carb aware.' The system currently supports Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring sensor, and the new agreement deepens the ongoing partnership between Beta Bionics and Abbott. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. The new dual sensor is currently under development and is built on the same form factor as Abbott's FreeStyle Libre 3 Plus and will continuously monitor both glucose and ketone levels. Ketone monitoring is a crucial advancement as it can help detect early signs of diabetic ketoacidosis, which is a serious complication of diabetes. Abbott's dual glucose-ketone sensor has received FDA breakthrough device designation. Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells health care products. Beta Bionics Inc. (NASDAQ:BBNX) is a commercial-stage medical device company. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies
BrightSpring Health Services Inc. (NASDAQ:BTSG) is one of the best new stocks to buy now. On June 18, BrightSpring Health Services announced that its specialty pharmacy, called Onco360, has been chosen as the national pharmacy partner for several newly approved therapies. These innovative treatments target advanced cancers and rare genetic disorders. BrightSpring delivers care and clinical solutions to 400,000+ customers, clients, and patients daily across all 50 states. Onco360 will provide access, education, data, and expert support for patients suffering from advanced ovarian and lung cancers, as well as neurofibromatosis type 1. A medical technician using surgical robotics to perform minimally-invasive urologic surgery in an operating room. Onco360 has been selected as a pharmacy partner for the following specific medication therapies: GOMEKLI, which is approved for adult and pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas/PN not suitable for complete resection; AVMAPKI FAKZYNJA CO-PACK, which is approved for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer/LGSOC who have received prior systemic therapy; and IBTROZI, which is approved for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). BrightSpring Health Services Inc. (NASDAQ:BTSG) is a home and community-based healthcare services platform in the US that operates through 2 segments: Pharmacy Solutions and Provider Services. Onco360 is a national, independent Oncology Pharmacy and clinical support services company. While we acknowledge the potential of BTSG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Waystar Study Highlights AI's Critical Role, Proven ROI in Healthcare Payments
Waystar Holding Corp. (NASDAQ:WAY) is one of the best new stocks to buy now. On June 23, Waystar announced the findings of a commissioned study conducted by Forrester Consulting. The study is titled 'AI in Healthcare Payments Software: A Strategic Imperative,' and revealed that AI is becoming increasingly critical in revenue cycle management/RCM due to its proven impact and measurable ROI. The research shows acceleration in AI adoption within healthcare. 82% of healthcare leaders now consider AI an integral part of their RCM operations, with 70% identifying it as a top organizational priority. The study also found that AI is delivering improvements in key revenue cycle metrics, such as a 13% to 37% improvement in high-impact areas such as claim accuracy, denial prevention, workforce efficiency, and payment speed. A medical professional with a patient explaining the effects of neurostimulation treatments. Trust in AI is growing, with 60% of decision-makers reporting increased confidence since implementing AI. ~ 70% of healthcare leaders view AI as a high or critical organizational priority, and 60% plan to increase their AI investment. The study is based on responses from 300+ healthcare leaders and highlights a preference for existing RCM software partners when it comes to AI capabilities. Waystar serves ~30,000 clients and represents over 1 million distinct providers, including 16 of the top 20 institutions on the US News Best Hospitals list. Waystar Holding Corp. (NASDAQ:WAY) develops a cloud-based software solution for healthcare payments. While we acknowledge the potential of WAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data